Skip Navigation

Annals of Oncology 2008 19(9):1519-1521; doi:10.1093/annonc/mdn426
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boyle, P.
Right arrow Articles by Zheng, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyle, P.
Right arrow Articles by Zheng, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

editorial

Need for global action for cancer control

P. Boyle1,*, B. O. Anderson2, L. C. Andersson3, Y. Ariyaratne4, G.-R. Auleley5, M. Barbacid6, H. Bartelink7, J. Baselga8, K. Behbehani9, F. Belardelli10, A. Berns11, J. Bishop12, O. Brawley13, H. Burns14, M. Clanton15, B. Cox16, D. Currow17, J.-M. Dangou18, D. de Valeriola19, K. Dinshaw20, A. Eggermont21, J. Fitzpatrick22, M. Forstmane23, E. Garaci24, A. T. Gavin25, T. Kakizoe26, M. Kasler27, N. Keita28, D. Kerr29, D. Khayat30, S. Khleif31, T. Khuhaprema32, T. Knezevic33, R. Kubinova34, M. Mallath35, J. Martin-Moreno36, D. McCance37, J. G. McVie38, A. Merriman39, T. Ngoma40, M. Nowacki41, J. Orgelbrand42, J.-G. Park43, M. Pierotti44, L. P. Ashton45, P. Puska46, C. V. R. Escobar47, B. Rajan48, T. Rajkumar49, U. Ringborg50, C. Robertson51, A. Rodger52, L. Roovali53, L. A. Santini54, M. Sarhan55, J. Seffrin56, V. Semiglazov57, B. M. Shrestha58, K. C. Soo59, V. Stamenic60, C. Tamblyn61, R. Thomas62, M. Tuncer63, T. Tursz64, R. Vaitkiene65, C. Vallejos66, U. Veronesi67, A. Wojtyla68, D. Yach69, K.-Y. Yoo70, W. Zatonski71, D. Zaridze72, Y.-X. Zeng73, P. Zhao74 and T. Zheng75

1 International Agency for Research on Cancer, Lyon, France
2 Breast Health Clinic, University of Washington, Seattle, WA, USA
3 The Finnish Cancer Institute, University of Helsinki, Finland
4 National Cancer Control Programme, Narahenpita, Colombo, Sri Lanka
5 Département de la Recherche Clinique et Innovations, Institut National du Cancer, Boulogne Billancourt, France
6 Director, Spanish National Cancer Research Centre (CNIO), Spain
7 Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
8 Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, Spain
9 The Geneva Foundation for Diseases of the Tropics, Geneva, Switzerland
10 Department of Cellular Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy
11 Netherlands Cancer Institute, Amsterdam, The Netherlands
12 Cancer Institute NSW, Alexandria, Australia
13 American Cancer Society, Atlanta, GA, USA
14 Chief Medical Officer, Scottish Executive Health Department, Edinburgh, UK
15 High Plains Division, American Cancer Society, Austin, TX, USA
16 New Zealand Cancer Control Trust, Dunedin, New Zealand
17 Palliative and Supportive Care, Funders University, Adelaide, Australia
18 National Cancer Control Programme of Senegal, Department of Pathology, Cheikh Anta Diop University, Dakar, Senegal
19 Institut Jules Bordet, Brussels, Belgium
20 Tata Memorial Centre, Mumbai, India
21 Department of Surgical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
22 Mater Misericordiae Hospital and University College Dublin, Dublin, Ireland
23 Division of Medical Treatment, Ministry of Health, Riga, Latvia
24 Istituto Superiore di Sanità and Alliance Against Cancer, Rome, Italy
25 Northern Ireland Cancer Registry, Queen's University Belfast, Belfast, UK
26 National Cancer Center, Tokyo, Japan
27 National Institute of Oncology, Budapest, Hungary
28 Centre Régional Francophone de Formation à la Prévention des Cancers Gynécologiques, Conakry, Guinée
29 Rhodes Professor of Clinical Pharmacology and Cancer Therapeutics, Department of Clinical Pharmacology, University of Oxford, Oxford, UK
30 Département d'Oncologie, Hôpital Pitié-Salpêtrière, Paris, France
31 King Hussein Institute for Cancer and Biotechnology, Amman, Jordan
32 National Cancer Institute, Bangkok, Thailand
33 Institute of Public Health of Serbia, Belgrade, Republic of Serbia
34 National Institute of Public Health, Prague, Czeck Republic
35 Tata Memorial Centre, Mumbai, India
36 Department of Preventive Medicine and Public Health, University of Valencia Medical School, Valencia, Spain
37 Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, UK
38 European Institute of Oncology, Milan, Italy
39 International Policy and Programmes, Hospice Africa Uganda, Kampala, Uganda
40 Ocean Road Cancer Institute, Dar es Salaam, United Republic of Tanzania
41 Marie Sktodowska-Curie Memorial Cancer Institute, Warsaw, Poland
42 Chief Sanitary Inspectorate, Warsaw, Poland
43 Seoul National University College of Medicine, Seoul, Republic of Korea
44 Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
45 National Institute of Neoplastic Disease (INEN), Lima, Peru
46 National Public Health Institute – KTL, Helsinki, Finland
47 National Cancer Institute, Bogota, Colombia
48 Regional Cancer Centre, Trivandrum, Kerala, India
49 Cancer Institute (WIA), Adyar, Chennai, India
50 Cancer Center Karolinska, Karolinska Institute, Stockholm, Sweden
51 Strathclyde University, Glasgow, UK
52 Beatson West of Scotland Cancer Centre, Glasgow, UK
53 Health Information and Analysis Department, Ministry of Social Affairs of Estonia, Tallinn, Estonia
54 National Cancer Institute/Ministry of Health, Rio de Janeiro, Brazil
55 King Hussein Cancer Center, Amman, Jordan
56 American Cancer Society, Atlanta, USA
57 N.N. Petrov Research Institute of Oncology, Saint Petersburg, Russian Federation
58 B.P. Koirala Memorial Cancer Hospital, Chitwan, Nepal
59 National Cancer Centre, Singapore, Singapore
60 Ministry of Health and Social Welfare, Zagreb, Croatia
61 Cancer Control Council of New Zealand, Wellington, New Zealand
62 Division of Surgical Oncology, Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia
63 Department of Cancer Control, Ministry of Health, Ankara, Turkey
64 Institut Gustave Roussy, Villejuif, France
65 Ministry of Health of the Republic of Lithuania, Vilnius, Lithuania
66 National Institute of Neoplastic Diseases, Lima, Peru
67 European Institute of Oncology, Milan, Italy
68 Chief Sanitary Inspectorate, Warsaw, Poland
69 Global Health Policy, PepsiCo Inc., Purchase, NY, USA
70 Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
71 Division of Cancer Epidemiology and Prevention, Cancer Centre and Institute of Oncology, Warsaw, Poland
72 Institute of Carcinogenesis, N.N. Blokhin Cancer Research Centre, Moscow, Russian Federation
73 Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China
74 China National Cancer Institute, Beijing, People's Republic of China
75 Division of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, USA

* (E-mail: director@iarc.fr)

The first 10% of the full text of this article appears below.

When the Millennium Development Goals (MDGs) [1] were being developed, priority was given to the problems of the poorest billion people in the world. In terms of health, this was translated into a set of targets of indicators in health that give visibility to maternal and child health, (under) nutrition, acquired immunodeficiency syndrome (AIDS), malaria, and tuberculosis, and a vague catch-all category, ‘and other diseases’. While progress has been made in developing specific plans with budgets to address the named MDG targets, no further work has been carried out on defining what constitute priority other diseases, or which interventions should be emphasized to address . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?